| Literature DB >> 33083520 |
Carla Piano1, Marco Ciavarro2, Francesco Bove1,3, Daniela Di Giuda4,5, Fabrizio Cocciolillo4, Anna Rita Bentivoglio1,3, Beatrice Cioni3,6, Tommaso Tufo6, Paolo Calabresi1,3, Antonio Daniele1,3.
Abstract
Electric Extradural Motor Cortex Stimulation (EMCS) is a neurosurgical procedure suggested for treatment of patients with advanced Parkinson's disease (PD). We report two PD patients treated by EMCS, who experienced worsening of motor symptoms and cognition 5 years after surgery, when EMCS batteries became discharged. One month after EMCS restoration, they experienced a subjective improvement of motor symptoms and cognition. Neuropsychological assessments were carried out before replacement of batteries (off-EMCS condition) and 6 months afterward (on-EMCS condition). As compared to off-EMCS condition, in on-EMCS condition both patients showed an improvement on tasks of verbal episodic memory and backward spatial short-term/working memory task, and a decline on tasks of selective visual attention and forward spatial short-term memory. These findings suggest that in PD patients EMCS may induce slight beneficial effects on motor symptoms and cognitive processes involved in verbal episodic memory and in active manipulation of information stored in working memory.Entities:
Keywords: Neurophysiology; Neuroscience
Year: 2020 PMID: 33083520 PMCID: PMC7522271 DOI: 10.1038/s41531-020-00129-8
Source DB: PubMed Journal: NPJ Parkinsons Dis ISSN: 2373-8057
Motor assessment, Levodopa Equivalent Daily dose, and anti-parkinsonian drugs.
| Patient 1 | Patient 2 | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | 60-month follow-up | 66 months off-EMCS | 72 months on-EMCS | Baseline | 60-month follow-up | 66 months off-EMCS | 72 months on-EMCS | |
| UPDRS off-med | 34 | 36 | 39 | 36 | 21 | 26 | 39 | 35 |
| UPDRS on-med | 16 | 23 | 23 | 23 | 16 | 25 | 27 | 27 |
| LEDD | 1257 | 979 | 1335 | 1219 | 1450 | 1175 | 700 | 850 |
| Pharmacological treatment | –Levodopa/ entacapone 825 mg/die –Ropinirole 8 mg/die | –Levodopa/ entacapone 300 mg/die –Amantadine 300 mg –Rotigotine 6 mg | –Levodopa/ entacapone 575 mg/die –Levodopa 150 mg/die –Safinamide 100 mg/die –Amantadine 200 mg –Rotigotine 4 mg | –Levodopa/ entacapone 300 mg/die –Levodopa 400 mg/die –Safinamide 100 mg/die –Amantadine 200 mg –Rotigotine 4 mg | –Levodopa 1250 mg/die –Ropinirole 10 mg/die | –Levodopa 1075 mg/die –Rasagiline 1 mg/die | –Levodopa 600 mg/die –Rasagiline 1 mg/die | –Levodopa 750 mg/die –Rasagiline 1 mg/die |
Motor assessment by means of the Unified Parkinson’s Disease Rating Scale (UPDRS) part III, Levodopa Equivalent Daily dose (LEDD) and pharmacological treatment with anti-parkinsonian drugs.
Cognitive assessment.
| Test (Score Range) | Patient 1 | Patient 2 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | off-EMCS | on-EMCS | % Change | Baseline | off-EMCS | on-EMCS% | %Change | |||||||||
| CS | ES | CS | ES | CS | ES | off-EMCS vs. baseline | on-EMCS vs. off-EMCS | CS | ES | CS | ES | CS | ES | off-EMCS vs. baseline | on-EMCS vs. off-EMCS | |
| MMSE (0–30) | 29.5 | – | 29 | – | 30 | – | 28.5 | – | 27.9 | – | 27.9 | – | – | |||
| RAVLT Immediate Recall (0–75) | 39 | 3 | 31.9 | 1 | 40.3 | 3 | 43.7 | 4 | 45.7 | 4 | 53.2 | 4 | ||||
| RAVLT Delayed Recall (0–15) | 10.3 | 4 | 5.6 | 1 | 11.9 | 4 | 8.7 | 3 | 8.7 | 4 | 9.9 | 4 | – | |||
| Digit Span backward | 4 | 3 | 3.4 | 2 | 4.4 | 4 | 7 | 4 | 5.2 | 4 | 5.2 | 4 | – | |||
| Corsi Span Backward | 4 | 3 | 3.2 | 1 | 4.3 | 3 | 4.2 | 3 | 3.5 | 2 | 4.5 | 3 | ||||
| RPM ‘47 | 34 | 4 | 20.6 | 1 | 28.6 | 4 | 31.6 | 4 | 29.6 | 4 | 26.8 | 3 | ||||
| Semantic verbal fluency | 20 | 4 | 14.4 | 3 | 17.4 | 4 | 16.8 | 4 | 16.7 | 4 | 13.8 | 2 | ||||
| Letter verbal fuency | 25.2 | 3 | 27.9 | 3 | 22.9 | 2 | 33.1 | 4 | 20.3 | 1 | 20.5 | 1 | ||||
| Digit span forward | 5 | 4 | 5.4 | 4 | 4.4 | 1 | 6.1 | 4 | 6.3 | 4 | 7.3 | 4 | +16% | |||
| Corsi span forward | 4 | 1 | 5.4 | 3 | 4.4 | 2 | 4 | 1 | 5.2 | 4 | 4.3 | 1 | ||||
| MFCT: accuracy | 1 | – | 0.9 | – | 0.8 | – | 1 | – | 0.9 | – | 0.9 | – | ||||
| MFCT: false alarms | 0 | 4 | 0 | 4 | 2 | 1 | 0 | 4 | 0 | 4 | 1 | 3 | ||||
| MFCT: time | 40 | 4 | 58.7 | 4 | 264.4 | 0 | 41.2 | 4 | 68.8 | 4 | 72.8 | 4 | ||||
| Stroop (time) | 11.5 | 4 | 9 | 4 | 6.5 | 4 | 16.7 | 4 | 6.4 | 4 | 14.9 | 4 | ||||
| Stroop (errors) | 0 | 4 | 2.5 | 2 | 1.6 | 2 | – | 0 | 4 | 0 | 4 | 2.8 | 1 | – | – | |
| Copy of drawings | 9.5 | 3 | 8.6 | 2 | 9.6 | 3 | 8.8 | 2 | 9 | 2 | 9 | 2 | – | |||
| Copy of drawings with landmark | 69.3 | 4 | 58 | 0 | 67 | 2 | 69.8 | 4 | 68.3 | 3 | 68.3 | 3 | – | |||
For each variable, the percentage of changes (off-EMCS vs baseline and on-EMCS vs off-EMCS) shown in the table were obtained from each individual patient (Italics: decline = poorer performance; Bold: improvement = better clinical condition).
MMSE Mini-Mental State Examination, RPM ‘47 Raven’s Progressive Matrices ‘47, RAVLT Rey’s Auditory Verbal Learning Test, CS corrected scores, ES equivalent scores.
Fig. 1Position of the quadripolar electrode strip over the motor cortex.
The figure shows the quadripolar electrode strip in Patient 1 oriented along the craniocaudal axis of the precentral gyrus (a), placed bilaterally over the motor cortex (b).